Navigation Links
Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
Date:5/13/2010

onClick="var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='93665764';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.aezsinc.com">www.aezsinc.com. A replay will be available on the Company's website for 30 days following the live event.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 Spartan Bioscience announced ... RX CYP2C19 System . It detects CYP2C19 genetic mutations ... swab. , The Spartan RX CYP2C19 System is the ... been approved in Canada. Due to the system’s ease ... be used by healthcare professionals such as doctors, nurses, ...
(Date:10/30/2014)... Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), the leader ... company overview at the Nomura Biotechnology Conference on Thursday, November ... MA. A live webcast of the ... of the Company,s website, www.isispharm.com .  A replay will ... will be archived for a limited time. About ...
(Date:10/30/2014)... flooding that devastated a wide swath of Colorado last ... roads and other infrastructure had been upgraded or modernized, ... Colorado Denver. , "People need to understand the importance ... professor of structural engineering at the CU Denver College ... study. "There is an assumption that a bridge will ...
(Date:10/27/2014)... and TORONTO , Oct. 27, ... ) (OTCQB: GNBT) today announced two presentations demonstrating ... by its novel proprietary cancer immunotherapeutic AE37 vaccine ... cancer patients. The AE37 cancer vaccine is being ... Inc. ( www.antigenexpress.com ). The presentations are being ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
... and GERMANTOWN, Maryland, May 3, 2012 ... assay to detect rupture of fetal membranes (ROM)   - ... Novel FDA-cleared test is highly synergistic with ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) today announced ...
... ANGELES, May 3, 2012 MD+DI ( ... brand providing the medical device industry with the latest news ... for Best Cover in the Medical, Dental & Related ... May 2011 cover was also a finalist for the ...
... Corporation (Nasdaq: VRNM ), a leading industrial biotechnology ... today announced that it will release 2012 first ... close. In conjunction with the release, the Company will host ... at 5:00 p.m. ET. The call may be ...
Cached Biology Technology:QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio 2QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio 3QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio 4QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio 5MD+DI, the Global MedTech Industry Authority, Wins a 2012 Maggie for Best Cover in the Medical, Dental & Related Services/Trade Category 2Verenium Corporation To Announce First Quarter 2012 Financial Results 2
(Date:10/29/2014)... Researching the safety of nanoparticles is all the rage. ... topic, examining the question of whether titanium dioxide nanoparticles ... into the body, whether carbon nanotubes from electronic products ... to be or whether nanoparticles in food can get ... Public interest is great, research funds are flowing – ...
(Date:10/29/2014)... research potential of the Barcode of Life Data ... Biodiversity Data Journal (BDJ) used ... imported these into a human-readable text developed in manuscript ... were used to study the species distributions of ten ... , BOLD is originally designed to support the generation ...
(Date:10/29/2014)... new study on a large cohort of kidney cancer ... of the disease -- and reveals an apparent link ... cancer, particularly in Romania. , The research, by an ... and Genome Quebec Innovation Centre in Montreal, underscores the ... acid. The compound, found in plants of the Aristolochia ...
Breaking Biology News(10 mins):Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3
... Virology group at the Institute for Molecular Medicine Finland ... national and international collaborators, developed a new cell screening ... drugs. The researchers were able to identify two novel ... the efficacy of a previously known drug saliphenylhalamide. ...
... to discontinue in 2013 a unique environmental research project that ... topics for almost 40 years would be a "huge loss ... humanity." That,s the focus of a viewpoint article in ACS, ... Hering, D. L. Swackhamer and W. H. Schlesinger explain that ...
... on the Florida campus of The Scripps Research Institute have ... for one of the diseases closely linked to fragile X ... memory impairment, and is the only known single-gene cause of ... the journal ACS Chemical Biology September 4, 2012, ...
Cached Biology News:Harnessing anticancer drugs for the future fight against influenza 2Scripps Florida scientists design molecule that reverses some fragile X syndrome defects 2
... Forma's stainless steel rack ... adjustable mechanism that permits ... shaking angles, and "snap-in" ... universal rack holder will ...
... Source: Escherichia coli RY 13 5'G AATTC3' 3'CTTAA ... 15 min or ethanol precipitation. Storage Conditions: 10mM ... DTT, 0.15% Triton X-100, 0.01% BSA, 50% glycerol. ... at -20C. Unit Definition: One unit is defined ...
... shaker flask clips, purpose-designed to firmly retain ... clips are equipped with a top retainer ... a bottom retainer spring, and silicon tubing ... glassware. Clips include the required mounting ...
ANTI DIPHTH TOX A SU...
Biology Products: